Extensive biomarker discoveries for DMD have occurred in the past 7 years, and a vast array
of these biomarkers were confirmed in independent cohorts and across different …

Non-invasive biological indicators of the absence/presence or progress of the disease that
could be used to support diagnosis and to evaluate the effectiveness of treatment are of …

Serum biomarkers in Duchenne muscular dystrophy (DMD) may provide deeper insights
into disease pathogenesis, suggest new therapeutic approaches, serve as acute read-outs …

Assessments of disease progression and response to therapies in Duchenne muscular
dystrophy (DMD) patients remain challenging. Current DMD patient assessments include …

Duchenne muscular dystrophy (DMD) is caused by loss of dystrophin in muscle, and while
all patients share the primary gene and biochemical defect, there is considerable patient …

Background: Duchenne Muscular Dystrophy is a severe, incurable disorder caused by
mutations in the dystrophin gene. The disease is characterized by decreased muscle …

Serum metabolite profiling in Duchenne muscular dystrophy (DMD) may enable discovery of
valuable molecular markers for disease progression and treatment response. Serum …

Duchenne muscular dystrophy is the most common form of muscular dystrophy. Genetic and
biochemical research over the years has characterized the cause, pathophysiology and …

Background Analysis of muscle biopsies allowed to characterize the pathophysiological
changes of Duchenne and Becker muscular dystrophies (D/BMD) leading to the clinical …

Steroids represent the only pharmacological palliative treatment for Duchenne muscular
dystrophy. However, they do have side effects and despite a large number of published …